AC
RNAM

Athanor Capital’s Avidity Biosciences RNAM Stock Holding History

Athanor Capital’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,523
Closed -$269K – 1008
2020
Q4 		$269K Sell
10,523
-636
-6% -$18.5K 0.01% 593
2020
Q3 		$314K Buy
11,159
+3,314
+42% +$95.8K 0.01% 413
2020
Q2 		$222K Buy
+7,845
New +$226K 0.01% 477

Other funds holding RNAM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Athanor Capital's RNAM Position: Q1 2021 in Review

Athanor Capital sold out of Avidity Biosciences (RNAM) in Q1 2021, closing a stake of 10,523 shares — an estimated $269K sold.

Athanor Capital first reported a position in RNAM in Q2 2020 and held it in 3 quarters. The position peaked at $314K in Q3 2020. 100 funds tracked by Wall St. Rank hold RNAM as of Q1 2021.

  • Athanor Capital reported no remaining Avidity Biosciences position as of Q1 2021 after selling out during the quarter.
  • Athanor Capital sold 10,523 Avidity Biosciences shares in Q1 2021, an estimated $269K.
  • Athanor Capital first reported a position in Avidity Biosciences in Q2 2020 and held it in 3 quarters.
  • Athanor Capital's Avidity Biosciences position peaked at $314K in Q3 2020.
  • 100 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.